break the dendron tie, page-7

I expect that Prima will be well above the 'micro cap' level by the time 4 months before the release of the stage III results are released. They've only just recruited their first patient.

Market cap at Fridays close of .20 is $213M AUD (USD 225M) which is 3/4 of the way to $300M, and 1/4 of the way to the $1B mark. If it hits the 40c mark that many are predicting after the NASDAQ listing, they will be well above the microcap level. The research quoted 2 out of 11 positive results for the mid tier ($300M to $1B).
If you want to read that article like a form guide, Prima are at about 5 to 1 to hit the big time, maybe a bit less coz they might not get to the $300M mark first. The returns will be much better than $1 per share if the phase III trial is successful.